U.S., Sept. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07193394) titled 'Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer' on Sept. 12.
Brief Summary: The H3RAKLES trial would allow patients with a progressive metastatic breast cancer to have access to one more line of systemic therapy. Patients included in this trial will have already received at least two lines of chemotherapy (and potentially several lines of endocrine therapy for patients with a HR+ disease). In this setting, few treatments have demonstrated a clinically meaningful benefit, and any additional option is valuable. Furthermore, the pre-clinical and clinical rationale indicate a high probability o...